Vertex Pharmaceuticals Stock Forecast, Price & News

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 2 sell ratings, 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vertex Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Vertex Pharmaceuticals saw a increase in short interest in August. As of August 13th, there was short interest totaling 5,040,000 shares, an increase of 20.3% from the July 29th total of 4,190,000 shares. Based on an average trading volume of 2,450,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 2.0% of the company's stock are sold short.
View Vertex Pharmaceuticals' Short Interest.

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Thursday, July, 29th. The pharmaceutical company reported $3.11 earnings per share for the quarter, beating analysts' consensus estimates of $2.25 by $0.86. The pharmaceutical company had revenue of $1.79 billion for the quarter, compared to the consensus estimate of $1.71 billion. Vertex Pharmaceuticals had a net margin of 29.80% and a trailing twelve-month return on equity of 29.73%.
View Vertex Pharmaceuticals' earnings history.

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VRTX stock has decreased by 15.1% and is now trading at $187.10.
View which stocks have been most impacted by COVID-19.

Vertex Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7.20 billion-$7.40 billion, compared to the consensus revenue estimate of $6.99 billion.

23 Wall Street analysts have issued 12-month price targets for Vertex Pharmaceuticals' shares. Their forecasts range from $175.00 to $331.00. On average, they anticipate Vertex Pharmaceuticals' stock price to reach $266.61 in the next twelve months. This suggests a possible upside of 42.5% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals or view top-rated stocks among Wall Street analysts.

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Incyte (INCY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of VRTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Vertex Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.00%), Vanguard Group Inc. (7.81%), Price T Rowe Associates Inc. MD (5.05%), State Street Corp (4.51%), Alliancebernstein L.P. (2.46%) and FMR LLC (2.25%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals.

VRTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Price T Rowe Associates Inc. MD, Capital International Investors, Alliancebernstein L.P., BlackRock Inc., Avoro Capital Advisors LLC, Point72 Asset Management L.P., and Clearbridge Investments LLC. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Michael Parini, Paul M Silva, Sangeeta N Bhatia, and Stuart A Arbuckle.
View insider buying and selling activity for Vertex Pharmaceuticals or view top insider-selling stocks.

VRTX stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Macquarie Group Ltd., Deutsche Bank AG, Amundi, Impax Asset Management Group plc, Parnassus Investments CA, Canada Pension Plan Investment Board, and State Street Corp. Company insiders that have bought Vertex Pharmaceuticals stock in the last two years include Bruce I Sachs, and Reshma Kewalramani.
View insider buying and selling activity for Vertex Pharmaceuticals or or view top insider-buying stocks.

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRTX stock can currently be purchased for approximately $187.10.

Vertex Pharmaceuticals has a market capitalization of $48.54 billion and generates $6.21 billion in revenue each year. The pharmaceutical company earns $2.71 billion in net income (profit) each year or $9.03 on an earnings per share basis.

Vertex Pharmaceuticals employs 3,400 workers across the globe.

The following companies are subsidiares of Vertex Pharmaceuticals: Aurora Biosciences Corporation, Exonics Therapeutics, Semma Therapeutics, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, Vertex Holdings Inc., Vertex Pharmaceuticals (Australia) Pty. Ltd., Vertex Pharmaceuticals (CH) GmbH, Vertex Pharmaceuticals (Canada) Incorporated, Vertex Pharmaceuticals (Cayman 509) Limited, Vertex Pharmaceuticals (Cayman 765) Limited, Vertex Pharmaceuticals (Cayman 787) Limited, Vertex Pharmaceuticals (Cayman II) Limited, Vertex Pharmaceuticals (Cayman III) Limited, Vertex Pharmaceuticals (Cayman) Limited, Vertex Pharmaceuticals (Czech Republic) s.r.o, Vertex Pharmaceuticals (Delaware) LLC, Vertex Pharmaceuticals (Distribution) Incorporated, Vertex Pharmaceuticals (Europe) Limited, Vertex Pharmaceuticals (France) SAS, Vertex Pharmaceuticals (Germany) GmbH, Vertex Pharmaceuticals (Ireland) Limited, Vertex Pharmaceuticals (Italy) S.r.L., Vertex Pharmaceuticals (Netherlands) B.V., Vertex Pharmaceuticals (Poland) sp. z.o.o, Vertex Pharmaceuticals (Portugal) Unipessoal Lda., Vertex Pharmaceuticals (Puerto Rico) LLC, Vertex Pharmaceuticals (San Diego) LLC, Vertex Pharmaceuticals (Singapore) Pte. Ltd., Vertex Pharmaceuticals (Spain) S.L., Vertex Pharmaceuticals (Sweden) AB, Vertex Pharmaceuticals (Switzerland) Sàrl, Vertex Pharmaceuticals (U.K.) Limited, Vertex Pharmaceuticals GmbH, Vertex Pharmaceuticals Single Member Societe Anonyme, and Vertex Securities Corporation.

Vertex Pharmaceuticals was founded in 1989.

The official website for Vertex Pharmaceuticals is www.vrtx.com.

Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210.

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100 or via email at [email protected]